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Randomised Trial
S.H.A.J. Tytgat,1 D.M. Laman,2* A.M. Rijken,1 R. Klicks,1 A. Voorwinde,1 J.M. Ultee1
and H. Van Duijn2Departments of 1Surgery, and 2Clinical Neurophysiology, St Lucas Andreas Hospital, Jan Tooropstraat 164,
1061 AE Amsterdam, The NetherlandsPurpose. To investigate whether a single pre-operative dose of 120 mg acetylsalicylic acid (ASA) decreased either (1) emboli
rate, as detected by transcranial Doppler (TCD), during and early after carotid endarterectomy (CEA) and (2) clinical intra-
and post-operative signs suggestive of embolism or increased bleeding tendency.
Design. Prospective, double-blind placebo controlled trial.
Patients and methods. One-hundred consecutive patients were randomised to receive either 120 mg ASA (nZ48) or
placebo (nZ49) by suppository on the night before CEA; three patients were excluded. Emboli were counted and expressed as
emboli rate (ER). The incidence of bleeding complications was assessed. Surgeons were asked to indicate which patients had
received ASA or placebo.
Results. There were no significant differences between the ASA and placebo groups in ER in the intraoperative and
postoperative periods. ER higher than 0.9 minK1 was associated with a significantly increased risk of complications (26 vs.
0%, P!0.01). No extra bleeding complications were observed in the ASA group. Surgeon assessment of whether or not ASA
had been administered had a sensitivity of 42% and a specificity of 70%.
Conclusion. A single pre-operative dose of ASA (120 mg) did not reduce significantly the emboli rate during and after CEA
and surgeons could not correctly identify whether or not ASA had been administered.Keywords: Emboli; Carotid endarterectomy; Acetylsalicylic acid; Transcranial Doppler sonography; Randomised controlled
trial.Introduction
Platelet aggregation inhibitors are widely used for
secondary stroke prevention and to reduce the risk of
re-infarction after a previous myocardial infarct.1 In
carotid surgery, a single dose of acetylsalicylic acid
(ASA) administered the evening before surgery has
been reported to reduce neurological events.2 The risk
of mortality and stroke after carotid endarterectomy
(CEA) is 6.3–8.1%,3 and thromboembolism is reported
to be the most important pathogenic factor in stroke
associated with CEA.4–7 Because ASA may reduce the
risk of thromboembolic events, we investigateding author. D.M. Laman, Department of Clinical
logy, St Lucas Andreas Hospital, Jan Tooropstraat 164,
terdam, The Netherlands.
: m.laman@slaz.nl
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could reduce the number of embolic signals detected
by transcranial Doppler (TCD) after carotid surgery
and thus reduce the incidence of cerebrovascular
complications. Because bleeding may be a compli-
cation of ASA, we also monitored the effect of ASA on
bleeding events and asked surgeons whether they
could identify, during surgery, which patients had
been treated with ASA.Patients and Methods
During a 4-year period, 100 consecutive patients who
were scheduled for carotid surgery were randomised.
Ninety-four patients had aS80% stenosis and 6 had a
60–80% stenosis of the ipsilateral carotid artery, as
assessed by duplex scanning. A contralateral occlusionEur J Vasc Endovasc Surg 29, 156–161 (2005)
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Emboli Rate in CEA After a Single Dose of ASA 157was present in 9 patients. Three randomised patients
were excluded (one a TCD monitoring failure because
of absence of acoustic window, two with allergy to
ASA). Forty-eight patients were assigned to the ASA
group and 49 to the placebo group. Ipsilateral
symptomatic carotid artery disease was present in 82
patients (amaurosis fugax, nZ11, transient ischemic
attack, nZ29, minor stroke Rankin8%2), nZ32, major
stroke (Rankin8 3–4), nZ10). Fifteen patients under-
went surgery for an asymptomatic carotid stenosis, 4
of whom had had symptoms in the territory of the
contralateral carotid artery.
All patients were treated with acenocoumarol, and
the use of aspirin was discontinued, at least 9 days
before surgery (median ASA group, 21 days, range 9–
66; median placebo group, 30, range 10–92, PZ0.09,
Mann–Whitney). Randomisation was provided by the
hospital pharmacist. The pharmacist had manufac-
tured sequentially numbered suppositories (Witepsol
H15, Bufa bv, Uitgeest, The Netherlands), which
contained either 120 mg ASA or placebo according to
a pre-constructed random treatment allocation list.
Once a patient had consented to the trial, they received
a (consecutive) number, this number was conveyed to
the pharmacist. The matching suppository was sent to
the ward and was administered to the patient the night
before operation. Both the patient and the medical
personnel were blinded as to which treatment the
patient had received. The randomisation key was
disclosed after completion of the trial.
All procedures were performed under general
anaesthesia. All patients received systemic heparin
(5000 IU), without reversal by protamine sulphate.
Standard carotid endarterectomy was performed. A
venous patch was always used for closure of the
arteriotomy.
TCD (EME 2-64 B, Eden Medizinische Technik,
Ueberlingen, Germany) monitoring of the ipsilateral
middle cerebral artery was performed with a 2 MHz
pulsed wave transducer attached to the ipsilateral
temple during the operation and was kept in situ in the
recovery room. A shunt was used during the operation
if after cross-clamping the ipsilateral middle cerebral
artery (MCA) mean blood flow velocity decreased to
30% or less of the preclamping mean blood flow
velocity in the MCA.
We investigated the occurrence of emboli in three
periods: the dissection period, from skin incision until
carotid clamping; the wound closure period, from
3 min after restoration of the internal carotid artery
flow until the end of the operation; and the post-
operative period.6 Patients were monitored for 20 min
in the recovery room. All TCD signals were stored on
tape for off-line analysis. Embolic signals wereidentified according to the criteria of the Consensus
Committee of the Ninth International Cerebral Hemo-
dynamic Symposium.9 The number of emboli counted
in each period is expressed as the emboli rate (ER) in
emboli/minute (e/min). All patients underwent a
neurological evaluation, including classification
according to the modified Rankin scale,8 by a board-
certified neurologist (DML) before the operation and
in the postoperative period, as soon as the patient
regained consciousness. This was repeated if the
patient had not fully recovered from general anaes-
thesia. The last two neurological evaluations were 2
days and 3 months after surgery. Study endpoints
were TIA (defined as symptoms lasting less than 24 h),
minor stroke (defined as symptoms lasting longer than
24 h and Rankin score %2), major stroke (defined as
severe permanent impairment affecting daily func-
tioning and RankinS3), and death.
Statistical analysis used Mann–Whitney, Pearson
Chi-square and Fischer exact tests, with SPSSq for
Windowse (release 11.0, SPSS Inc., Chicago, IL) (2003),
and Instat 2.05 (Graphpad Software Inc., San Diego,
CA). Differences were considered significant at P!
0.05.
All patients gave their informed consent before
surgery. The ethics committee of our institution
approved this study.Results
The flow of patients through the trial is shown in Fig.
1. There were no significant differences in the
distribution of the stroke classification between the
ASA and placebo groups (Table 1). The groups were
well matched for age, sex, smoking habit, incidence of
hypertension, ischaemic heart disease, diabetes,
hypercholesterolaemia, and dysbasia (Table 2). There
was a non-significant trend for the placebo group to
have a higher International Normalized Ratio (INR)
(1.5 ASA group vs. 1.9 placebo group, PZ0.069,
Mann–Whitney; Table 2).
Emboli were detected in 56% of the patients in the
dissection period (48% in the ASA group; 62% in the
placebo group). These emboli were detected during
the wound closure period in 47% patients (53% in the
ASA group; 40% in the placebo group), and during
the post-operative period in 76% of the patients in the
postoperative period (78% in the ASA group; 75% in
the placebo group). The emboli rates in all three
periods were not significantly different between the
ASA and the placebo groups (Fig. 2, Table 3). In each
group, the emboli rate (ER) in the three periods
differed significantly (postoperativeOdissectionOEur J Vasc Endovasc Surg Vol 29, February 2005
Fig. 1. CONSORT diagram showing flow of patients through the trial.
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groups, P!0.0001). Only in the placebo group during
the postoperative period was there a significant
difference (Mann–Whitney, PZ0.023) between the ER
of men and women. The difference in ER during the
postoperative period between ASA and placebo in
women was not statistically significant (PZ0.163,
Table 3). There was an increase in ER during three
periods (dissection, wound closure and postoperative)
for shunt versus no shunt in the placebo group, most
significant in the postoperative period (PZ0.001).
There were no significant differences between the ER
of the subgroups in the dissection period of the
placebo group or in the three periods of the ASA
group.
Cerebrovascular complications occurred in 6Table 1. Distributions of the pre-operative stroke classification and
contralateral carotid artery occlusion between the ASA and
placebo groups
ASA (nZ48) Placebo (nZ49) Pa
Asymptomatic 10 5 0.175
Amaurosis fugax 6 5 0.759
TIA 16 13 0.512
Minor stroke
(Rankin (2)
12 20 0.131
Major stroke
(Rankin 3–4)
4 6 0.740
Contralateral
carotid artery
occlusion
4 5 0.743
a Fisher exact test.
Eur J Vasc Endovasc Surg Vol 29, February 2005patients (6.2%), three in the ASA group (one TIA,
one minor stroke, one major stroke) and three in the
placebo group (one TIA, two minor strokes) (Table 4).
All these complications were recognized in the
recovery room. Two complications became apparent
immediately after the patients regained consciousness:
both were men and had their highest ER during the
dissection period. The other four patients developed
complications within 2 h after surgery, and had their
highest ER during the postoperative monitoring
period. Median interval between restoration of the
internal carotid artery circulation and the start of
monitoring in the postoperative period was 51 min
(range 31–240 min, third quartile 62 min) and was not
significantly different between the two groups (Mann–
Whitney test, PZ0.97).Table 2. Patient characteristics
ASA Placebo P
Age 68.1 (49–83) 68.0 (45–80) 0.91a
Sex M/F 33/15 31/18 0.57b
Smoking 52% 57% 0.61b
Hypertension 60% 69% 0.77b
Ischaemic heart disease 54% 36% 0.09b
Diabetes 15% 18% 0.66b
Dysbasia 15% 20% 0.45b
Hypercholesterolaemia 27% 35% 0.42b
Shunt 7 (15%) 10 (20%) 0.59c
INR (median; mean; SD;
range)
1.5; 1.7; 0.51;
1.1–3.5
1.9; 1.9; 0.64;
1–3.8
0.069a
a Mann–Whitney test.
b Pearson Chi-square test.
c Fisher exact test.
Fig. 2. Boxplots (SPSSw) of emboli rate (ER) during dissection
period (DP), wound closure period (WP) and postoperative
period (PP) in placebo and ASA groups. Outliers and
extremes are hidden. Medians and ranges: see Table 3.
Table 4. Complications
ASA Placebo Pa
TIA 1 1 NS (1.0)
Minor stroke 1 2 NS (1.0)
Major stroke 1 0 NS (0.49)
Death 0 0
Postoperative occlusion 0 2 NS (0.49)
Bleeding complications 2 2 NS (1.0)
Total complications 5 7 NS (0.76)
a Fisher exact test.
Emboli Rate in CEA After a Single Dose of ASA 159There was no significant difference in the number of
complications, including the number of venous bleeds
after surgery, between the two groups (Table 4). The
length of the wound closure period was not different
between the two groups (Mann–Whitney test, PZ
0.877) and even when only the upper 10th percentile
(O30 min) was considered there was no difference
between the groups (Fisher exact test, P 0.435, odds
ratio 2.68, 95% CI, 0.493–14.564). Venous bleeding at
the site of surgery occurred in four patients (two each
in the ASA and placebo groups). The INRs of these
patients were 1.3, 2.9, 3.5, and 3.8, respectively.
Data from both groups were combined to evaluateTable 3. ER in the three periods
Emboli rate
(ER)
ASA Placebo Pa
DPall 0.02 (0–1.67) 0.04 (0–2.36) 0.271
Women 0.00 (0–0.43) 0.02 (0–1.78) 0.735
Men 0.02 (0–1.67) 0.06 (0–2.36) 0.24
WPall 0.00 (0–0.25) 0.00 (0–2.05) 0.96
Women 0.00 (0–0.14) 0.045 (0–2.05) 0.23
Men 0.04 (0–0.25) 0.00 (0–0.2) 0.39
PPALL 0.15 (0–3.8) 0.25 (0–7.5) 0.25
Women 0.15 (0–3.8) 0.6 (0–7.5)b 0.163
Men 0.15 (0–2.5) 0.2 (0–5.25)b 0.85
Emboli rates (ER) in the 3 periods with subdivision into women and
men are reported as median and range (between brackets). DP,
dissection period; WP, wound closure period; PP, postoperative
period.
a Mann–Whitney tests.
b PZ0.023 (Mann–Whitney test, women versus men in PP; placebo
group).the risk of cerebrovascular complications in relation to
the ER. Patients were then stratified into two groups
according to the number of ER: group I!0.9 e/min
(nZ74; ASA: nZ38, placebo: nZ36),) and group II,
S0.9 e/min (nZ23; ASA: nZ10, placebo: nZ13).6
There was no significant association between either
the ASA or placebo groups and stratification into
group I or II (Fisher exact test, PZ0.634). More
cerebrovascular complications occurred in group II:
26 vs. 0% (P!0.0001, odds ratio 55.3, 95% CI 3–1030,
Fisher exact test).
Surgeons were not able to identify those patients
treated with ASA (specificity for ASA use 70%;
sensitivity 42%, positive predictive value of 58%;
negative predictive value of 55%).Discussion
A single pre-operative dose of 120 mg ASA did not
significantly reduce the ER or the number of patients
with emboli during and after carotid endarterectomy.
The patient characteristics of the two groups were
comparable. As shown in an earlier study, a high
number of embolic signals correlated with a higher
incidence of cerebrovascular complications.6,10 The
number of cerebrovascular complications (6.2%) may
seem rather high. One possible explanation for this
was that a neurologist made both the pre- and
postoperative neurological assessments. This is
known to result in a higher complication rate than
assessment by surgical staff.11 In the present study,
there were three minor strokes, (Rankin%2), two
transient ischemic attacks (TIA) and one major stroke
(RankinO2). One TIA (in the placebo group) would
not have been noticed if the neurological assessment
had been postponed until the end of the day of
surgery, in which case the complication rate would
have reduced to 5.1% (major stroke 1%).
In two patients the neurological deficit was present
at awakening. Both had their highest ER in the
dissection period. In the other four patients the
complications developed within 2 h after surgery,Eur J Vasc Endovasc Surg Vol 29, February 2005
S. H. A. J. Tytgat et al.160and they had their highest ER in the postoperative
monitoring period. This supports the correlation of
high ER and cerebrovascular complications. In both
groups, the ER was higher and more patients had
emboli during the postoperative period than during
the other periods.
The significant difference (PZ0.023) in ER between
women and men in the placebo group during the
postoperative period was not observed in the ASA
group. Therefore, although the difference in ER during
the postoperative period between women in the two
groups was not significant, one could infer that ASA
had a more pronounced anti-embolic effect in women
than in men. A significantly higher ER was found only
in the subgroup with a shunt in the placebo group
compared with the no shunt placebo group. However,
the numbers are small; therefore the clinical signifi-
cance is unclear.
Human and animal studies have shown that
platelet deposition is increased at the site of CEA,
reaching a maximum 20 min to 1 h after exposure to
Indium-111 labelled platelets.12,13 Embolism from the
operative site during CEA is considered the principal
cause of cerebrovascular complications.5 Levi et al.
found emboli to be most prevalent in the early (within
1 h) postoperative period, with a strong association
between a high emboli count in this period and the
development of ischaemic stroke.10 In our study, the
median interval (51 min) between the restoration of
internal carotid artery flow and the start of post-
operative monitoring fell into this range, suggesting
that the timing of the start of monitoring was
appropriate for detection of emboli.
ASA inhibits platelet aggregation and many sur-
geons believe that its use causes noticeable intrao-
perative oozing and increases operative bleeding
complications. Indeed, this commonly held opinion
has led many clinics to withdraw ASA before surgery.
However, ASA prevents vascular events in patients
who have had a TIA or minor stroke. Because low and
medium doses are equally effective,14 but side-effects
are dose related,15 we used a moderate dose of 120 mg
ASA, aiming at an antithrombotic effect without
promoting gastrointestinal complications.14,16 This
dose may have been too low to establish a clear result.
In the study by Lindblad et al. (1993), 75 mg aspirin
was given the evening before carotid surgery.2 This
reduced the incidence of postoperative stroke without
complete recovery within a week.2 Although in the
present study a higher dose of ASA was given, a clear
effect on the ER and clinical complications was not
seen. However, the patients in the study of Lindblad
had also received dextran 40 during, and 3 days afterEur J Vasc Endovasc Surg Vol 29, February 2005the operation, which is known to reduce emboli in the
postoperative period.17
We did not investigate the effects of the single dose
of ASA on platelet function using aggregation tests.
Previous studies have shown the effect of ASA on
platelet aggregation to be dose dependent, with non-
response occurring in about 10% of cases.18–20 Differ-
ences between men and women in this respect have
not been reported. There was a large variation in the
number of postoperative embolic signals registered,
ranging from 0 to 3.8 in the ASA group to 0–7.5 in the
placebo group. The number of patients may have been
too small to detect a significant decrease in embolic
signals. Moreover, the data were not normally dis-
tributed, which meant that reliable power calculations
were not possible.
A recently published study in which 100 CEA
patients on routine aspirin therapy (150 mg) were
randomised to 75 mg clopidogrel or placebo the night
before surgery, reported a significant reduction of
postoperative emboli in the clopidogrel group.21
Because clopidogrel has a different way of platelet
aggregation inhibition than ASA,22 this study reported
on a combined effect on emboli versus the effect of
ASA alone. It remains to be seen whether clopidogrel
alone will have the same anti-embolic effect as in
combination with ASA.
We had anticipated an increased bleeding tendency
as a side effect of ASA. This was not seen in our study.
The length of the wound closure period, which can be
considered an indirect marker for hemostasis,21 was
not different between the two groups, even if we
considered only the upper 10th percentile. In the study
of Payne et al.21 Clopidogrel did prolong the wound
closure period. This may reflect the intrinsic differ-
ences between ASA and clopidogrel, as reported by
Hayes et al.23 Furthermore, 3 of the 4 patients with
(venous) bleeding had a high INR. Acenocoumarol is
an anticoagulant with relatively short half life (11 h), so
fluctuations in the INR are more prone to happen than
with anticoagulants with long half life, such as
phenprocoumon.
The surgeons, who were unaware of which drug
had been administered, could not identify which
patients had been given ASA. No differences in
bleeding complications were seen between the two
groups. This is in accordance with the findings of West
et al.24 Therefore we conclude that ASA can be safely
administered preoperatively, without the risk of
additional bleeding complications, as reported ear-
lier.2 Moreover, our findings confirm that a post-
operative ER higher than 0.9 minK1 should be
considered a warning signal for cerebrovascular
complications.6
Emboli Rate in CEA After a Single Dose of ASA 161Conclusion
A single preoperative dose of 120 mg ASA did not
provide a significant decrease in the ER or the number
of patients with emboli during and after carotid
endarterectomy. ASA did not affect the number of
cerebrovascular or bleeding complications. Surgeons
could not correctly identify patients who had received
ASA. Further prospective studies, preferably with
higher doses of ASA and with more patients are
needed to elucidate the role of ASA in reducing the
occurrence of emboli during and shortly after carotid
endarterectomy.Acknowledgements
S.H.A.J.T. and D.M.L. have equally contributed to the design,
analysis, data interpretation of this study, and writing the
article. We thank M.A.J. van Duijn, PhD, for her statistical
expertise and G.H. Wieneke, PhD, for his critical remarks.
There is no conflict of interest.References
1 Antithrombotic Trialists’ Collaboration. Collaborative meta-
analysis of randomised trials of antiplatelet therapy for preven-
tion of death, myocardial infarction and stroke in high risk
patients. BMJ 2002;324:71–86.
2 Lindblad B, Persson NH, Takolander R, Bergqvist D. Does
low-dose acetylsalicylic acid prevent stroke after carotid surgery?
A double-blind, placebo-controlled randomized trial. Stroke 1993;
24:1125–1128.
3 Rothwell PM, Eliasziw ME, Gutnikov SA, Fox AJ, Taylor DW,
Mayberg MR, Warlow CP, Barnett HJM, for the Carotid
Endarterectomy Trialists Collaboration. Analysis of pooled data
from the randomised controlled trials of endarterectomy for
symptomatic carotid stenosis. Lancet 2003;361:107–116.
4 Steed DL, Peitzman AB, Grundy BL, Webster MW. Causes of
stroke in carotid endarterectomy. Surgery 1982;92:634–641.
5 Spencer MP. Transcranial Doppler monitoring and causes of
stroke from carotid endarterectomy. Stroke 1997;28:685–691.
6 Laman DM, Wieneke GH, Van Duijn H, Van Huffelen AC.
High embolic rate early after carotid endarterectomy is associ-
ated with early cerebrovascular complications, especially in
women. J Vasc Surg 2002;36:278–284.
7 Krul JMJ, Van Gijn J, Ackerstaff RGA, Eikelboom BC,
Theodorides T, Vermeulen FEE. Site and pathogenesis of infarct
associated with carotid endarterectomy. Stroke 1989;20:324–328.
8 Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA,
Van Gijn J. Interobserver agreement for the assessment of
handicap in stroke patients. Stroke 1988;19:604–607.9 Consensus Committee of the Ninth International Cerebral
Hemodynamic Symposium. Basic identification criteria of
Doppler microembolic signals. Stroke 1995;26:1123.
10 Levi CR, O’Malley HM, Fell G, Roberts AK, Hoare MC,
Royle JP et al. Transcranial Doppler detected cerebral micro-
embolism following carotid endarterectomy: high microembolic
signal load predicts postoperative cerebral ischaemia. Brain 1997;
120:621–629.
11 Rothwell PM, Slattery J, Warlow CP. A systematic review of
the risks of stroke and death due to carotid endarterectomy for
symptomatic carotid stenosis. Stroke 1996;27:260–265.
12 Stratton JR, Zierler RE, Kazmers A. Platelet deposition at
carotid endarterectomy sites in humans. Stroke 1987;18:722–727.
13 Falk GL, Gray-Weale AC, Meyer HJ, Lohnson S, Lusby RJ.
Carotid endarterectomy. The timing of perioperative therapy by
indium111 labelled platelets study in canines. J Cardiovasc Surg
1988;29:697–700.
14 The Dutch TIA Trial Study Group. A comparison of two doses of
aspirin (30 mg vs 283 mg a day) in patients after a transient
ischemic attack or minor ischemic stroke. N Engl J Med 1991;
325:1261–1266.
15 UK-TIA Study Group. The United Kingdom transient ischemic
attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg
Psychiatry 1991;54:1044–1054.
16 Patrono C, Ciabattoni G, Patrignani P, Pugliese F,
Filabozzi P, Catella F, Davi G, Forni L. Clinical pharmacology
of platelet cyclooxygenase inhibition. Circulation 1985;72:1177–
1184.
17 Naylor AR, Hayes PD, Allroggen H, Lennard N, Gaunt ME,
Thompson MM, London NJM, Bell PRF. Reducing the risk of
carotid surgery: a 7-year audit of the role of monitoring and
quality control assessment. J Vasc Surg 2000;32:750–759.
18 Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients.
Evidence of nonresponders in a subpopulation of treated
patients. Thromb Res 1991;63:587–593.
19 Helgason CM, Tortorice KL, Winkler SR, Penney DW,
Schuler JJ, McClelland TJ, Brace LD. Aspirin response and
failure in cerebral infarction. Stroke 1993;24:345–350.
20 Syrbe G, Redlich H, Weidlich B, Ludwig J, Kopitzsch S,
Gockefitz A, Herzog T. Individual dosing of ASA prophylaxis
by controlling platelet aggregation. Clin Appl Thromb Hemost
2001;7:209–213.
21 Payne DA, Jones CI, Hayes PD, Thompson MM, London NJ,
Bell PR, Goodall AH, Naylor AR. Beneficial effects of
clopidogrel combined with aspirin in reducing cerebral emboli
in patients undergoing carotid endarterectomy. Circulation 2004;
109:1476–1481.
22 Lenz TL, Wilson AF. Clinical pharmacokinetics of antiplatelet
agents used in the secondary prevention of stroke. Clin
Pharmocokinet 2003;42:909–920.
23 Hayes PD, Box H, Tull S, Bell PR, Goodall A, Naylor AR.
Patients thromboembolic potential after carotid endarterectomy
is related to the platelets sensitivity to adenosine diphosphate.
J Vasc Surg 2003;38:1226–1231.
24 West SW, Otley CC, Nguyen TH, Phillips PK, Roenigk RK,
Byrd DR, Asp E, Weaver AL. Cutaneous surgeons cannot predict
blood-thinner status by intraoperative visual inspection. Plast
Reconstr Surg 2002;110:98–103.
Accepted 11 November 2004Eur J Vasc Endovasc Surg Vol 29, February 2005
